Drugs@FDA: FDA-Approved Drugs
Company: PFIZER
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
MYCOBUTIN | RIFABUTIN | 150MG | CAPSULE;ORAL | Prescription | AB | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
12/23/1992 | ORIG-1 | Approval | Type 1 - New Molecular Entity | PRIORITY; Orphan |
Label is not available on this site. |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
09/15/2021 | SUPPL-26 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s026lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050689Orig1s026ltr.pdf | |
03/08/2021 | SUPPL-25 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050689Orig1s025ltr.pdf | |
07/01/2015 | SUPPL-22 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050689s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/050689Orig1s022ltr.pdf |
11/13/2014 | SUPPL-18 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050689Orig1s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/050689Orig1s018ltr.pdf | |
05/14/2008 | SUPPL-16 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/050689s016ltr.pdf | |
01/29/2001 | SUPPL-14 | Manufacturing (CMC)-Control |
Label is not available on this site. |
||
11/09/2001 | SUPPL-13 | Labeling |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/50689s13ltr.pdf |
01/15/1999 | SUPPL-12 | Manufacturing (CMC) |
Label is not available on this site. |
||
11/09/2001 | SUPPL-11 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50689s11s13lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/50689s13ltr.pdf | |
09/13/1996 | SUPPL-10 | Manufacturing (CMC) |
Label is not available on this site. |
||
11/03/1995 | SUPPL-8 | Labeling |
Label is not available on this site. |
||
01/11/1996 | SUPPL-7 | Manufacturing (CMC)-Packaging |
Label is not available on this site. |
||
06/06/1994 | SUPPL-6 | Manufacturing (CMC)-Control |
Label is not available on this site. |
||
05/31/1994 | SUPPL-5 | Manufacturing (CMC)-Control |
Label is not available on this site. |
||
09/08/1995 | SUPPL-4 | Manufacturing (CMC)-Expiration Date |
Label is not available on this site. |
||
06/22/1993 | SUPPL-3 | Manufacturing (CMC)-Control |
Label is not available on this site. |
||
07/28/1993 | SUPPL-2 | Manufacturing (CMC) |
Label is not available on this site. |
||
07/26/1993 | SUPPL-1 | Labeling |
Label is not available on this site. |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
09/15/2021 | SUPPL-26 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s026lbl.pdf | |
03/08/2021 | SUPPL-25 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s025lbl.pdf | |
07/01/2015 | SUPPL-22 | Labeling-Package Insert | Label (PDF) | Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050689s022lbl.pdf |
11/13/2014 | SUPPL-18 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050689Orig1s018lbl.pdf | |
05/14/2008 | SUPPL-16 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf | |
11/09/2001 | SUPPL-11 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50689s11s13lbl.pdf |
MYCOBUTIN
CAPSULE;ORAL; 150MG
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
MYCOBUTIN | RIFABUTIN | 150MG | CAPSULE;ORAL | Prescription | Yes | AB | 050689 | PFIZER |
RIFABUTIN | RIFABUTIN | 150MG | CAPSULE;ORAL | Prescription | No | AB | 090033 | LUPIN LTD |
RIFABUTIN | RIFABUTIN | 150MG | CAPSULE;ORAL | Prescription | No | AB | 215041 | NOVITIUM PHARMA |